Immune & Antimicrobial

PGLa

PGLa comes from the same African clawed frog skin as the magainins, and its distinguishing property is teamwork. Alone it is one more membrane-piercing peptide; mixed with magainin 2 in equal amounts, the concentration needed to inhibit Escherichia coli falls roughly tenfold, because the two pair up into a joint structure inside the membrane that neither forms by itself. Working out the shape of that structure is what most of the PGLa literature does, in all-atom simulations of transient hourglass-shaped pores opening and closing. It is also the limit of the record: everything on file was measured in bacterial cultures, artificial lipid membranes, or computer models of them, and no animal has been treated with PGLa, let alone a person.

Last updated 12 August 2026

Studied forAntibacterial research · Membrane permeabilisation studies · Peptide synergy research

Evidence on file3 computational studies

Strongest sourcePGLa and Magainin 2 Can Porate Membranes via Transient Hourglass-Shaped Toroidal Pores. (computational study)

Mechanism

Folds into an amphipathic helix that inserts into anionic bacterial membranes, forming transient pores; synergistic with magainin 2.

Reported effects

What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.

Antibacterial research
Membrane permeabilisation studies
Peptide synergy research

Dosing on file unverified

No established human dose; preclinical only

Carried from a source that labels it unverified, and reproduced with that label attached. A record of what is reported, not a recommendation. No citation on this page establishes it.

Literature on file 3

computational
PGLa and Magainin 2 Can Porate Membranes via Transient Hourglass-Shaped Toroidal Pores. graded on: a computational prediction — read from the indexed abstract — “molecular dynamics”
computational
Flexible Tail of Antimicrobial Peptide PGLa Facilitates Water Pore Formation in Membranes. graded on: all-atom molecular dynamics simulations with deep-learning intermediate identification — read from the abstract — “abstract review”
computational
Binding and dimerization of PGLa peptides in anionic lipid bilayer studied by replica exchange molecular dynamics. graded on: a computational prediction — “molecular dynamics”

Identity

Space-filling 3D model of PGLa, carbon grey, nitrogen blue, oxygen red — Built from the SMILES on this record — the atoms and bonds are exact. The shape is **one computed low-energy pose**, not a measured structure: a flexible peptide in solution has no single conformation, and where the SMILES leaves a stereocentre undefined the pose commits to one arbitrarily. The skeletal formula below claims connectivity and nothing more, which is what we actually know.

2D chemical structure of PGLa — Built from the SMILES on this record — the atoms and bonds are exact. The shape is **one computed low-energy pose**, not a measured structure: a flexible peptide in solution has no single conformation, and where the SMILES leaves a stereocentre undefined the pose commits to one arbitrarily. The skeletal formula below claims connectivity and nothing more, which is what we actually know.

Molecular weight: 1968.5
Molecular formula: C88H162N26O22S
CAS number: 102068-15-5
PubChem CID: 16131010
InChI key: PJRSUKFWFKUDTH-JWDJOUOUSA-N
SMILES: CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)CN
InChI: InChI=1S/C88H162N26O22S/c1-19-48(9)69(113-78(126)52(13)97-66(117)42-95-72(120)50(11)98-79(127)59(31-23-27-36-91)108-85(133)64(44-115)111-77(125)54(15)100-81(129)61(33-38-137-18)104-65(116)41-93)87(135)101-51(12)73(121)96-43-67(118)105-57(29-21-25-34-89)82(130)114-70(49(10)20-2)88(136)103-55(16)74(122)106-60(32-24-28-37-92)83(131)112-68(47(7)8)86(134)102-56(17)76(124)110-63(40-46(5)6)84(132)107-58(30-22-26-35-90)80(128)99-53(14)75(123)109-62(71(94)119)39-45(3)4/h45-64,68-70,115H,19-44,89-93H2,1-18H3,(H2,94,119)(H,95,120)(H,96,121)(H,97,117)(H,98,127)(H,99,128)(H,100,129)(H,101,135)(H,102,134)(H,103,136)(H,104,116)(H,105,118)(H,106,122)(H,107,132)(H,108,133)(H,109,123)(H,110,124)(H,111,125)(H,112,131)(H,113,126)(H,114,130)/t48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,68-,69-,70-/m0/s1

Notes unverified prose

No human trials identified; research only; no established human dosing protocol; No human trials; preclinical only

Not on file 3

1 of the 8 fields we track hold nothing on this record, and each says why. 2 further absences are named below. A blank field is a bug; a named absence is a finding.

amino-acid sequencenothing we hold supplies it
half-lifenothing we hold supplies it
route of administrationnothing we hold supplies it

Each field links to every other record missing the same thing. The full ledger holds 765 gaps across 163 records.